Kee-Hong Kim

Kee-Hong Kim's Title

Kee-Hong Kim serves as the Chief Technology Officer (CTO) at Tenaya Therapeutics. Since joining the company in 2018, he has been instrumental in steering the technological advancements and strategic initiatives that support Tenaya's mission of developing life-saving therapies. His extensive background in process development and technical operations makes him a pivotal figure in the biotech industry.

Kee-Hong Kim's Company

Tenaya Therapeutics is a biotechnology company that focuses on developing transformative therapies for heart disease. Kee-Hong Kim's role as CTO involves overseeing the technological and operational aspects of the company's innovative projects. Under his leadership, Tenaya Therapeutics has made significant strides in research and development, leveraging cutting-edge technologies to address unmet medical needs in cardiovascular health.

Kee-Hong Kim's Education and Expertise

Kee-Hong Kim holds a doctoral degree in chemical engineering from Colorado State University and completed his post-doctoral training at Cornell University. His academic background provides a robust foundation for his expertise in gene therapy, process development, and manufacturing science. His specialized knowledge in these areas has been critical in advancing the capabilities of several biotech firms.

Kee-Hong Kim's Background

With a rich history in the biopharmaceutical sector, Kee-Hong Kim has held various significant roles. Before joining Tenaya Therapeutics, he was the Senior Vice President and Head of Technical Operations at Agilis Biotherapeutics. He also served as the Head of Gene Therapy Process Development and Global CMC Lead at Shire. His experience extends to running his own biopharma consulting firm, directing process development at Avalanche Biotechnology (now Adverum), and contributing to the development of Dendreon's PROVENGE™.

Kee-Hong Kim's Achievements

Kee-Hong Kim has a remarkable track record of achievements in the biotech industry. At Dendreon, he played a crucial role in the process development and regulatory filings for PROVENGE™, a groundbreaking commercial product. His leadership at various organizations, including Aeras TB Foundation and Walter Reed Army Medical Center, has been marked by innovative advancements in gene therapy and biopharma operations. His work continues to impact the field significantly, driving forward the development of novel therapeutic solutions.